A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

Also called NCT07584967

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
AnaCardio AB (from the registry)
Registry
  • NCT NCT07584967
  • EU CT 2025-524469-25-00
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Bulgaria, Canada, Czechia, Poland, Slovakia, Spain, Sweden (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07584967. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-15 (anticipated); primary completion 2028-07-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
Acronym
GOAL-HF2
Intervention (Drug)
AC01
Intervention (Other)
Placebo
Lead sponsor
AnaCardio AB (class: industry)

Record details

Record id
cardio:ct-nct07584967
Content hash
02928d8c5498c52892116f6057fd24960501f3195657108eca0ab45ae1ea39fa